AI Article Synopsis
- Immunotherapeutic strategies, especially T-cell-redirected therapies, have significantly impacted the treatment of multiple myeloma, particularly in patients with relapsed/refractory cases.
- The 20th annual IMS meeting featured a session focusing on the practical applications of approved CAR-T therapies and bispecific antibodies, emphasizing their use in frontline treatment.
- Key discussion topics included managing acute toxicities, preventing infections, and optimizing the sequencing of these innovative therapies.
Article Abstract
Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2024.03.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!